In 2025, 50% of Europeans are expected to suffer from Asthma or other chronic allergic disease. That’s one of the reasons MIcompany has started a collaboration with the UMCG (Universitair Medisch Centrum Groningen) in the field of DNA research to unravel the mysteries behind asthma and other allergic diseases. In a joint research team we strive for medical breakthroughs that enable better prediction of allergy risk and insights for the development of new medicines. This cross-border collaboration is described in the attached PDF article, revealing the exciting opportunities and medical relevance of DNA research.
Interested to find out more? We also attached a double-interview in the Financieel Dagblad with the initiators of this collaboration, prof. dr. Gerard Koppelman of the UMCG and MIcompany founder Marnix Bügel PhD.